176 related articles for article (PubMed ID: 30829867)
1. Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients.
Verma P; Malhotra G; Goel A; Rakshit S; Chandak A; Chedda R; Banerjee S; Asopa RV
Clin Nucl Med; 2019 May; 44(5):e318-e322. PubMed ID: 30829867
[TBL] [Abstract][Full Text] [Related]
2. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract][Full Text] [Related]
3. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
[TBL] [Abstract][Full Text] [Related]
4. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Meshram V; Chandak A; Sonavane S; Lila AR; Bandgar TR; Asopa RV
Clin Nucl Med; 2021 Aug; 46(8):e406-e409. PubMed ID: 33883490
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.
Sasikumar A; Joy A; Pillai MR; Nanabala R; Anees K M; Jayaprakash PG; Madhavan J; Nair S
Clin Nucl Med; 2017 Jan; 42(1):e41-e48. PubMed ID: 27846000
[TBL] [Abstract][Full Text] [Related]
9. Utility of 68Ga-PSMA-11 PET/CT in Imaging of Glioma-A Pilot Study.
Sasikumar A; Kashyap R; Joy A; Charan Patro K; Bhattacharya P; Reddy Pilaka VK; Oommen KE; Pillai MRA
Clin Nucl Med; 2018 Sep; 43(9):e304-e309. PubMed ID: 29939953
[TBL] [Abstract][Full Text] [Related]
10. Uptake in sympathetic ganglia on
Kanthan GL; Hsiao E; Vu D; Schembri GP
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):732-738. PubMed ID: 28623872
[TBL] [Abstract][Full Text] [Related]
11.
van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
[No Abstract] [Full Text] [Related]
12. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Test-Retest Measurement of
Pollard JH; Raman C; Zakharia Y; Tracy CR; Nepple KG; Ginader T; Breheny P; Sunderland JJ
J Nucl Med; 2020 Aug; 61(8):1145-1152. PubMed ID: 31806776
[TBL] [Abstract][Full Text] [Related]
14. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122
[TBL] [Abstract][Full Text] [Related]
15. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
16. PET/CT using
Liu D; Cheng G; Ma X; Wang S; Zhao X; Zhang W; Yang W; Wang J
J Neuroimaging; 2021 Jul; 31(4):733-742. PubMed ID: 34021667
[TBL] [Abstract][Full Text] [Related]
17. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
18.
Akgun E; Akgun MY; Selçuk HH; Uzan M; Sayman HB
Eur J Radiol; 2020 Sep; 130():109199. PubMed ID: 32763474
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer.
Pyka T; Weirich G; Einspieler I; Maurer T; Theisen J; Hatzichristodoulou G; Schwamborn K; Schwaiger M; Eiber M
J Nucl Med; 2016 Mar; 57(3):367-71. PubMed ID: 26585062
[TBL] [Abstract][Full Text] [Related]
20. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.
Kumar A; ArunRaj ST; Bhullar K; Haresh KP; Gupta S; Ballal S; Yadav M; Singh M; Damle NA; Garg A; Tripathi M; Bal C
Neuroradiology; 2022 May; 64(5):969-979. PubMed ID: 34648046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
